Related Experiment Video
Updated: May 4, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Canagliflozin: a new hope in the antidiabetic armamentarium
Vasiliki K Katsi, Christos A Michalakeas, Charalambos E Grassos
1Cardiology Department, Hippocratio Hospital, Greece, Vas. Sofias Avenue 114, Post code: 11527, Athens, Greece. vkkatsi@yahoo.gr.
Abstract:
Canagliflozin-with the patent number WO2011142478A1- belongs to a novel class of antidiabetic drugs known as SGLT2 inhibitors, which has been approved by FDA in March 2013. This medication acts through the inhibition of glucose reabsorption in the kidney resulting in glucosuria and thus lowering of glucose blood levels. There are several phase III clinical ongoing trials involving this new class of medications. So far promising results have been shown. This review article summarizes current knowledge regarding the novel SGLT2 inhibitor canagliflozin and its future perspectives in the treatment of type 2 diabetes mellitus.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Glinides
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Sulfonylureas
